BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 11360105)

  • 1. A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer.
    Laport GG; Fleming GF; Waggoner S; Zimmerman TM; Grinblatt DL; Williams SF
    Bone Marrow Transplant; 2001 Apr; 27(7):677-81. PubMed ID: 11360105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.
    Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V
    Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization of peripheral blood stem cells in high-risk breast cancer patients using G-CSF after standard dose docetaxel.
    Fleming DR; Goldsmith J; Goldsmith GH; Stevens DA; Herzig RH
    J Hematother Stem Cell Res; 2000 Dec; 9(6):855-60. PubMed ID: 11177597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel effectively mobilizes peripheral blood CD34+ cells.
    Prince HM; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Wall D; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Rischin D
    Bone Marrow Transplant; 2000 Sep; 26(5):483-7. PubMed ID: 11019836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY.
    Weaver CH; Schwartzberg LS; Zhen B; Franco C; Moore M; Smith R; White L; Van Amburg A; Hazelton B; Buckner CD
    Bone Marrow Transplant; 1999 Mar; 23(5):421-5. PubMed ID: 10100554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients.
    Meehan KR; Slack R; Gehan E; Herscowitz HB; Areman EM; Ebadi M; Cairo MS; Lippman ME
    J Hematother Stem Cell Res; 2002 Apr; 11(2):415-21. PubMed ID: 11983113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
    Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
    Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer.
    De Rosa L; Lalle M; Perillo A; Pierelli L; Salerno MG; Cortesi E; Martelli O; Pandolfi A; Amodeo R; Marzetti L; Mancuso S; Scambia G
    Anticancer Res; 2001; 21(2B):1367-70. PubMed ID: 11396215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
    De Giorgi U; Rosti G; Zaniboni A; Ballardini M; Minzi MR; Baioni M; Ferrari E; Zornetta L; Marangolo M
    Bone Marrow Transplant; 2003 Aug; 32(3):251-5. PubMed ID: 12858195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of hematopoietic progenitor cells with a combination of docetaxel, adriamycin, 5-fluorouracil and filgrastim in breast cancer patients.
    Pérez-Calvo J; Fernández-Hidalgo O; Subirá ML; Martín-Algarra S; Salgado E; Brugarolas A
    Haematologica; 2001 Jan; 86(1):100-1. PubMed ID: 11146579
    [No Abstract]   [Full Text] [Related]  

  • 14. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
    Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
    Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
    Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
    Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.
    Gajewski JL; Rondon G; Donato ML; Anderlini P; Korbling M; Ippoliti C; Benyunes M; Miller LL; LaTemple D; Jones D; Ashby M; Hellmann S; Durett A; Lauppe J; Geisler D; Khouri IF; Giralt SA; Andersson B; Ueno NT; Champlin R
    Biol Blood Marrow Transplant; 2002; 8(10):550-6. PubMed ID: 12434950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.